After surprise rejection of hemophilia gene therapy, BioMarin asks FDA to approve dwarfism drug
A controversial drug to treat the most common form of dwarfism is heading for a federal regulator's decision.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) of San Rafael said Thursday that it submitted its new drug application for the Food and Drug Administration to approve its drug, called vosoritide, as a once-daily injection for children with achondroplasia. The bone-growth disorder prevents cartilage fr om changing into bone.
The application comes a day after the FDA rejected BioMarin's request…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Ron Leuty Source Type: news
More News: Children | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Haemophilia | Health Management | Hemophilia | New Drug Applications | Pharmaceuticals